Annalisa G.
- Country
- Italy
- Department
- SC Oncologia
Research Overview
- Avelumab Maintenance Versus Best Supportive Care After Second-Line Platinum-Based Chemotherapy in Metastatic Urothelial Carcinoma (AVESEC Trial)
- A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab
- Phase II Open-Label Evaluation of Sacituzumab Govitecan in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma
Data & Insights
Has run more than one trial at 330 of 575 partner sites.
Specializations
Genitourinary oncology
Clinical research activity is strongly centered on urothelial carcinoma and renal cell carcinoma, with interest in advanced, metastatic, and unresectable disease settings. The therapeutic focus includes immunotherapy, targeted agents, and combination strategies in bladder cancer and kidney cancer.
- Urothelial carcinoma
- Renal cell carcinoma
- Muscle-invasive bladder cancer
- Metastatic clear cell renal cell carcinoma
- HER2-expressing urothelial cancer
Additional involvement includes prostate cancer and biomarker-defined disease such as MET-driven papillary renal cell carcinoma and mCRPC.
Hematologic malignancies
The investigator is active in studies of multiple myeloma, chronic lymphocytic leukemia, and lymphoma, spanning both newly diagnosed and relapsed or refractory disease. Research interest extends to antibody-based, B-cell–directed, and cellularly focused therapeutic approaches.
- Multiple myeloma
- Chronic lymphocytic leukemia
- Follicular lymphoma
- Diffuse large B-cell lymphoma
- Marginal zone lymphoma
Work also includes mantle cell lymphoma, plasmablastic lymphoma, and myelofibrosis, reflecting a broad therapeutic interest across malignant hematology.
Thoracic and breast cancer
Clinical trial involvement covers non-small cell lung cancer, small-cell lung cancer, and breast cancer, with emphasis on advanced and biomarker-selected populations. The therapeutic landscape includes immune checkpoint inhibition, targeted treatment, and endocrine-based strategies.
- Non-small cell lung cancer
- Small-cell lung cancer
- Hormone receptor-positive breast cancer
- HER2-negative advanced breast cancer
- EGFR mutation-positive lung cancer
Interest also includes adjuvant osimertinib, PIK3CA-mutated breast cancer, and metastatic triple-negative breast cancer.
Targeted and immune-based treatment innovation
The investigator’s portfolio reflects substantial engagement with therapies built around PD-1, PD-L1, CTLA-4, BTK inhibition, BCL-2 inhibition, and antibody-drug conjugates. These areas appear across solid tumors and hematologic cancers, with a strong translational emphasis.
- Immune checkpoint blockade
- Antibody-drug conjugates
- BTK inhibitor-based therapy
- BCL-2–directed treatment
- HER2-targeted approaches
Research activity also includes PARP-related and multi-agent combination regimens in advanced malignancies.
Selected non-oncology interests
Beyond oncology, the clinical research profile includes studies in Parkinson’s disease, atherosclerotic cardiovascular disease, pneumonia-associated myocardial injury, and peritoneal dialysis. These topics indicate participation in therapeutic areas linked to chronic neurologic, cardiovascular, and renal care.
- Parkinson’s disease
- Atherosclerotic cardiovascular disease
- Myocardial injury
- Peritoneal dialysis
- End-stage kidney disease
There is also involvement in kidney-related supportive care and metabolic risk management.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.